Articles published by Exscientia plc
![](https://mms.businesswire.com/media/20240815623767/en/2216695/5/Exscientia_logo-01.jpg)
![](https://mms.businesswire.com/media/20240718738353/en/2189068/5/Exscientia_logo-01.jpg)
![](https://mms.businesswire.com/media/20240710764372/en/2181602/5/Exscientia_logo-01.jpg)
![](https://mms.businesswire.com/media/20240606896916/en/2151803/5/Exscientia_logo-01.jpg)
![](https://mms.businesswire.com/media/20240530048166/en/2144535/22/Exscientia_Logo_for_BW.jpg)
![](https://mms.businesswire.com/media/20240521942319/en/2136790/22/Exscientia_Logo_for_BW.jpg)
Exscientia Business Update for First Quarter 2024
May 21, 2024
From Exscientia plc
Via Business Wire
Tickers
EXAI
![](https://mms.businesswire.com/media/20240514601711/en/2128896/22/Exscientia_Logo_for_BW.jpg)
![](https://mms.businesswire.com/media/20240321480832/en/2074560/22/Exscientia_Logo_for_BW.jpg)
![](https://mms.businesswire.com/media/20240314297594/en/2066172/22/Exscientia_Logo_for_BW.jpg)
![](https://mms.businesswire.com/media/20240228066057/en/2047034/22/Exscientia_Logo_for_BW.jpg)
Exscientia to Present at Upcoming Investor Conferences in March
February 28, 2024
From Exscientia plc
Via Business Wire
Tickers
EXAI
![](https://mms.businesswire.com/media/20240207431781/en/2024578/22/Exscientia_Logo_for_BW.jpg)
Exscientia Initiates Clinical Study to Further Evaluate Functional Precision Medicine Platform in Cancer Patients
February 07, 2024
From Exscientia plc
Via Business Wire
Tickers
EXAI
![](https://mms.businesswire.com/media/20231221360521/en/1976041/22/Exscientia_Logo_for_BW.jpg)
Exscientia Announces Expansion of its Current Collaboration with Sanofi to Include Existing Exscientia Programme
December 21, 2023
From Exscientia plc
Via Business Wire
Tickers
EXAI
![](https://mms.businesswire.com/media/20231205812217/en/1959442/22/Exscientia_Logo_for_BW.jpg)
Exscientia Receives Open Philanthropy Grant to Explore New Therapeutic Approach for Pandemic Influenza
December 05, 2023
From Exscientia plc
Via Business Wire
Tickers
EXAI
![](https://mms.businesswire.com/media/20231121531974/en/1949992/22/Exscientia_Logo_for_BW.jpg)
![](https://mms.businesswire.com/media/20231109551909/en/1940209/22/Exscientia_Logo_for_BW.jpg)
Exscientia Business Update for Third Quarter 2023
November 09, 2023
From Exscientia plc
Via Business Wire
Tickers
EXAI
![](https://mms.businesswire.com/media/20231102371588/en/1931759/22/Exscientia_Logo_for_BW.jpg)
![](https://mms.businesswire.com/media/20231012133441/en/1912856/22/Exscientia_Logo_for_BW.jpg)
Parker Moss to Join Exscientia as EVP, Corporate Development
October 17, 2023
From Exscientia plc
Via Business Wire
Tickers
EXAI
![](https://mms.businesswire.com/media/20231016372855/en/1915404/5/Exscientia_logo-01.jpg)
Exscientia to Present New Preclinical Data for AI-designed LSD1 and MALT1 Inhibitors at ESMO 2023
October 16, 2023
From Exscientia plc
Via Business Wire
Tickers
EXAI
![](https://mms.businesswire.com/media/20231003722128/en/1904496/22/Exscientia_Logo_for_BW.jpg)
Exscientia Details Pipeline Prioritisation Strategy
October 03, 2023
From Exscientia plc
Via Business Wire
Tickers
EXAI
![](https://mms.businesswire.com/media/20230919108369/en/1894425/22/Exscientia_Logo_for_BW.jpg)
Exscientia Announces AI Drug Discovery Collaboration with Merck KGaA, Darmstadt, Germany
September 20, 2023
From Exscientia plc
Via Business Wire
Tickers
EXAI
![](https://mms.businesswire.com/media/20230831530566/en/1878114/22/Exscientia_Logo_for_BW.jpg)
![](https://mms.businesswire.com/media/20230810421078/en/1863724/22/Exscientia_Logo_for_BW.jpg)
![](https://mms.businesswire.com/media/20230710425172/en/1836144/22/Exscientia_Logo_for_BW.jpg)
First Patient Enrolled in Phase 1/2 “ELUCIDATE” Trial Assessing GTAEXS617 in Advanced Solid Tumours
July 10, 2023
From Exscientia plc
Via Business Wire
Tickers
EXAI
![](https://mms.businesswire.com/media/20230606005192/en/1811125/22/Exscientia_Logo_for_BW.jpg)
![](https://mms.businesswire.com/media/20230524005210/en/1801576/5/Exscientia_logo-01.jpg)
Exscientia Business Update for First Quarter 2023
May 24, 2023
From Exscientia plc
Via Business Wire
Tickers
EXAI
![](https://mms.businesswire.com/media/20230522005110/en/1798771/5/Exscientia_logo-01.jpg)
![](https://mms.businesswire.com/media/20230517005202/en/1795876/22/Exscientia_Logo_for_BW.jpg)
![](https://mms.businesswire.com/media/20230515005508/en/1793428/22/Exscientia_Logo_for_BW.jpg)
Exscientia Announces Sixth Molecule Created Through Generative AI Platform to Enter Clinical Stage
May 15, 2023
From Exscientia plc
Via Business Wire
Tickers
EXAI
![](https://mms.businesswire.com/media/20230503005079/en/1780871/22/Exscientia_Logo_for_BW.jpg)
![](https://mms.businesswire.com/media/20230419005391/en/1767906/22/Exscientia_Logo_for_BW.jpg)
Data Presented at AACR 2023 Highlights Exscientia’s Clinical and Preclinical Development
April 19, 2023
From Exscientia plc
Via Business Wire
Tickers
EXAI
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.